Inhaled vitamin D could offer a new route to better lung health for millions of people living with chronic respiratory conditions, researchers have said, as they argue that the conventional oral supplements many patients take are unlikely to reach the tissues that need them most.
The COPD Foundation said this week that delivering the vitamin directly to the lungs via inhalation may improve lung function and reduce the frequency of flare-ups in people with diseases such as chronic obstructive pulmonary disease, cystic fibrosis and asthma. The potential benefit is significant: more than 35 million Americans suffer from these conditions, according to the American Lung Association, and in the UK the numbers are similarly stark. Official figures show asthma affects around 7.2 million people, COPD an estimated 3 million – with roughly two million of those undiagnosed – and cystic fibrosis more than 11,000, making it one of the country’s most common life-threatening inherited diseases.
Low levels of vitamin D, a nutrient that helps regulate the immune system, are known to raise the risk of respiratory infections, worsen lung function and trigger debilitating exacerbations. That has long pointed towards supplementation as a logical treatment. Yet despite strong epidemiological links between vitamin D deficiency and poor lung outcomes – studies have associated deficiency with higher odds of asthma, wheeze and lower lung function in British adults, and with increased mortality in older men with COPD – oral supplements have repeatedly failed to deliver clinically meaningful benefits in trials.
The vitamin D paradox: why oral supplements fall short
The problem, researchers at the University of North Carolina at Chapel Hill have identified, lies in what happens to vitamin D once it is swallowed. Unlike when it is absorbed through the skin after exposure to sunlight, oral vitamin D travels from the gut to the liver, where it is processed and released into the bloodstream. As the blood circulates towards the lungs, the vitamin appears to hit a biochemical barrier.
“Oral vitamin D is potentially inactivated by an enzyme in the lung’s blood vessels, preventing it from reaching the airways,” said Kevin Schichlein, a researcher at UNC’s Marsico Lung Institute. “We think direct delivery to the lungs could be a more effective option.”
This mechanism explains what respiratory specialists have come to call the “vitamin D paradox” – the puzzling gap between observational data linking deficiency to disease and the null results from randomised controlled trials of oral supplementation. Numerous large-scale studies have failed to show that raising blood levels of vitamin D through tablets improves lung function, reduces flare-ups or enhances quality of life for patients with chronic lung diseases. One notable exception, a study led by Queen Mary University of London, found a 45% reduction in lung attacks among COPD patients who were deficient in vitamin D at the start, but no benefit for those whose levels were already sufficient. Some research has also indicated that oral vitamin D may help improve steroid response in asthmatic patients with deficiency, but overall the evidence for routine supplementation remains weak.
Despite this well-documented failure, many patients continue to take vitamin D tablets. The NHS advises everyone in the UK to consider a daily supplement of 10 micrograms between October and March, when sunlight is too weak to produce enough vitamin D, and recommends year-round supplementation for at-risk groups including people with dark skin, those who are housebound or wear clothing that covers most of their skin, and pregnant or breastfeeding women. But for the specific purpose of treating chronic lung disease, these general guidelines have not translated into reliable therapeutic results.
Inhaled delivery: a targeted solution
The alternative proposed by the UNC team is to bypass the bloodstream entirely. Inhaling vitamin D as a fine mist or powder would deliver it directly to the airway epithelium – the layer of cells lining the lungs that possesses its own machinery for metabolising the vitamin. Preclinical studies in animals have already shown that inhaled or nebulised vitamin D can protect lung tissue against dust, pollution and pathogens, reduce inflammation, preserve the integrity of the epithelial barrier and improve overall lung function.
“Topical or inhaled delivery of vitamin D is already being explored for upper airway diseases, with data from preclinical models and some preliminary clinical trials showing promising results,” said Ilona Jaspers, a professor of paediatrics at the UNC School of Medicine. “Moving to the lower airways could be a logical extension of these observations.”
Beyond bypassing the inactivation enzyme, direct lung delivery may also help tackle the harmful inflammation that drives many major lung conditions. In its normal role, inflammation is the body’s defence against viruses and bacteria, but in chronic diseases it can become destructive – triggering genetic mutations, damaging lung tissue and blocking the flow of air. Inhaled vitamin D, researchers believe, could exert a local anti-inflammatory effect that oral supplements cannot achieve.
The COPD Foundation, which published the researchers’ perspective paper in its journal Chronic Obstructive Pulmonary Diseases, emphasised that these methods must now be tested in human clinical trials to determine safety, optimal dosing and long-term effectiveness. Work is needed to understand how inhaled vitamin D is absorbed, distributed, metabolised and excreted in humans, and to establish whether prolonged exposure could cause harm. But for the millions of patients whose lung function remains stubbornly poor despite standard treatments, the promise of a simple, targeted inhaled therapy represents a fresh direction worth pursuing.